SCHEMBL1008047

SCHEMBL1008047

CCOC(=O)CCc1ccccc1OCc1c(C)cccc1C

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.56
CYP4A11 Q02928 3/20 0.56
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
SLC22A12 Q96S37 1/20 0.43
DHFR P00374 1/20 0.42
SGMS2 Q8NHU3 1/20 0.41
GPR34 Q9UPC5 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ABCB1 P08183 1/20 0.41
NLRP3 Q96P20 1/20 0.40
LTB4R Q15722 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008570 0.86 TBXAS1 (0.51) CYP4F2CYP4A11ALDH1A1SLC22A12SGMS2
SCHEMBL1008500 0.85 PTGER4 (0.54) SLC22A12LTB4RLTB4R2
SCHEMBL16673226 0.84 CYP4F2 (0.67) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL16218017 0.81 CYP4F2 (0.56) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL13948404 0.80 CYP4F2 (0.73) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL16972794 0.80 CYP4F2 (0.60) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL19511165 0.79 PTGER4 (0.56) CYP4F2CYP4A11ABCB1LTB4RLTB4R2
SCHEMBL13566535 0.79 CYP4F2 (0.48) CYP4F2CYP4A11ALDH1A1GAAKDM4E
SCHEMBL7687145 0.79 CYP4F2 (0.67) CYP4F2CYP4A11ALDH1A1GAASMN1; SMN2
SCHEMBL2956872 0.78 CYP4F2 (0.58) CYP4F2CYP4A11ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-8829058-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2014-09-09 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 CYP4F2 392/4885CYP4A11 405/4885ALDH1A1 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.